{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:55:46Z","timestamp":1791932146162,"version":"4.3.4"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"F. Hoffmann\u2011La Roche Ltd. (Basel, Switzerland) provided financial support for the preparation, review, and approval of the manuscript."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11154-025-10014-5","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:11:02Z","timestamp":1771229462000},"page":"237-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3565-1167","authenticated-orcid":false,"given":"Daniel G.","family":"Ezra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Azumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-0630","authenticated-orcid":false,"given":"C\u00e9sar A.","family":"Brice\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1012-2293","authenticated-orcid":false,"given":"Fatemeh","family":"Rajaii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-0367","authenticated-orcid":false,"given":"Mario","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8757-2946","authenticated-orcid":false,"given":"Marco","family":"Sales-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3269-5719","authenticated-orcid":false,"given":"Oluwatobi O.","family":"Idowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"4","key":"10014_CR1","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367. https:\/\/doi.org\/10.1530\/EJE-21-0479.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10014_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s0002-9394(14)72666-2","volume":"120","author":"GB Bartley","year":"1995","unstructured":"Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. The incidence of Graves\u2019 ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol. 1995;120(4):511\u20137. https:\/\/doi.org\/10.1016\/s0002-9394(14)72666-2.","journal-title":"Am J Ophthalmol"},{"key":"10014_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ajo.2023.04.013","volume":"253","author":"S Ramesh","year":"2023","unstructured":"Ramesh S, Zhang QE, Sharpe J, Penne R, Haller J, Lum F, et al. Thyroid eye disease and its vision-threatening manifestations in the Academy IRIS Registry: 2014\u20132018. Am J Ophthalmol. 2023;253:74\u201385. https:\/\/doi.org\/10.1016\/j.ajo.2023.04.013.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10014_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1089\/thy.2022.0251","volume":"32","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32(12):1439\u201370. https:\/\/doi.org\/10.1089\/thy.2022.0251.","journal-title":"Thyroid"},{"issue":"1","key":"10014_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","volume":"100","author":"JJ Khong","year":"2016","unstructured":"Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1):142\u201350. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307399.","journal-title":"Br J Ophthalmol"},{"issue":"suppl 1","key":"10014_CR6","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","volume":"107","author":"TJ Smith","year":"2022","unstructured":"Smith TJ. Understanding pathogenesis intersects with effective treatment for thyroid eye disease. J Clin Endocrinol Metab. 2022;107(suppl 1):S13\u201326. https:\/\/doi.org\/10.1210\/clinem\/dgac328.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10014_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-024-03141-6","volume":"44","author":"K Rana","year":"2024","unstructured":"Rana K, Garg D, Yong LSS, Leyden J, Patel S, Slattery J, et al. Asymmetric proptosis in thyroid eye disease. Int Ophthalmol. 2024;44(1):206. https:\/\/doi.org\/10.1007\/s10792-024-03141-6.","journal-title":"Int Ophthalmol"},{"issue":"4S suppl 1","key":"10014_CR8","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1097\/IOP.0000000000001150","volume":"34","author":"PJ Dolman","year":"2018","unstructured":"Dolman PJ. Grading severity and activity in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S suppl 1):S34\u201340. https:\/\/doi.org\/10.1097\/IOP.0000000000001150.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"10014_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103534","volume":"23","author":"F Buonfiglio","year":"2024","unstructured":"Buonfiglio F, Ponto KA, Pfeiffer N, Kahaly GJ, Gericke A. Redox mechanisms in autoimmune thyroid eye disease. Autoimmun Rev. 2024;23(5):103534. https:\/\/doi.org\/10.1016\/j.autrev.2024.103534.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10014_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010072","volume":"13","author":"K Ciepli\u0144ska","year":"2023","unstructured":"Ciepli\u0144ska K, Niedziela E, Kowalska A. Immunological processes in the orbit and indications for current and potential drug targets. J Clin Med. 2023;13(1):72. https:\/\/doi.org\/10.3390\/jcm13010072.","journal-title":"J Clin Med"},{"issue":"3","key":"10014_CR11","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.survophthal.2021.08.010","volume":"67","author":"V Gupta","year":"2022","unstructured":"Gupta V, Hammond CL, Roztocil E, Gonzalez MO, Feldon SE, Woeller CF. Thinking inside the box: current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease. Surv Ophthalmol. 2022;67(3):858\u201374. https:\/\/doi.org\/10.1016\/j.survophthal.2021.08.010.","journal-title":"Surv Ophthalmol"},{"key":"10014_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993. https:\/\/doi.org\/10.3389\/fendo.2020.615993.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10014_CR13","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1089\/thy.1997.7.885","volume":"7","author":"MN Gerding","year":"1997","unstructured":"Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves\u2019 ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1997;7(6):885\u20139. https:\/\/doi.org\/10.1089\/thy.1997.7.885.","journal-title":"Thyroid"},{"issue":"1","key":"10014_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40123-020-00318-x","volume":"10","author":"Y Wang","year":"2021","unstructured":"Wang Y, Sharma A, Padnick-Silver L, Francis-Sedlak M, Holt RJ, Foley C, et al. Physician-perceived impact of thyroid eye disease on patient quality of life in the united States. Ophthalmol Ther. 2021;10(1):75\u201387. https:\/\/doi.org\/10.1007\/s40123-020-00318-x.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"10014_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/archopht.123.4.491","volume":"123","author":"M Farid","year":"2005","unstructured":"Farid M, Roch-Levecq AC, Levi L, Brody BL, Granet DB, Kikkawa DO. Psychological disturbance in Graves ophthalmopathy. Arch Ophthalmol. 2005;123(4):491\u20136. https:\/\/doi.org\/10.1001\/archopht.123.4.491.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10014_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cxo.12472","volume":"100","author":"DL Weiler","year":"2017","unstructured":"Weiler DL. Thyroid eye disease: a review. Clin Exp Optom. 2017;100(1):20\u20135. https:\/\/doi.org\/10.1111\/cxo.12472.","journal-title":"Clin Exp Optom"},{"issue":"1","key":"10014_CR17","first-page":"36","volume":"6","author":"FF Rundle","year":"1957","unstructured":"Rundle FF. Management of exophthalmos and related ocular changes in Graves\u2019 disease. Metabolism. 1957;6(1):36\u201348.","journal-title":"Metabolism"},{"issue":"2","key":"10014_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1210\/edrv.21.2.0393","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C. Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168\u201399. https:\/\/doi.org\/10.1210\/edrv.21.2.0393.","journal-title":"Endocr Rev"},{"issue":"5","key":"10014_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/IOP.0000000000001087","volume":"35","author":"S Ugradar","year":"2019","unstructured":"Ugradar S, Rootman DB. Noninflammatory thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2019;35(5):461\u20134. https:\/\/doi.org\/10.1097\/IOP.0000000000001087.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"10014_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/IOP.0000000000001942","volume":"37","author":"NM I\u00f1iguez-Ariza","year":"2021","unstructured":"I\u00f1iguez-Ariza NM, Sharma A, Garrity JA, Stan MN. The quiet TED-a special subgroup of thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2021;37(6):551\u20135. https:\/\/doi.org\/10.1097\/IOP.0000000000001942.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"11","key":"10014_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012984.pub2","volume":"11","author":"S Hamed Azzam","year":"2018","unstructured":"Hamed Azzam S, Kang S, Salvi M, Ezra DG. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev. 2018;11(11):CD012984. https:\/\/doi.org\/10.1002\/14651858.CD012984.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10014_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1055\/s-0035-1554721","volume":"47","author":"M Salvi","year":"2015","unstructured":"Salvi M, Campi I. Medical treatment of Graves\u2019 orbitopathy. Horm Metab Res. 2015;47(10):779\u201388. https:\/\/doi.org\/10.1055\/s-0035-1554721.","journal-title":"Horm Metab Res"},{"issue":"12","key":"10014_CR23","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454\u201363. https:\/\/doi.org\/10.1210\/jc.2012-2389.","journal-title":"J Clin Endocrinol Metab"},{"key":"10014_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.754386","volume":"12","author":"G Elia","year":"2021","unstructured":"Elia G, Fallahi P, Ragusa F, Paparo SR, Mazzi V, Benvenga S, et al. Precision medicine in Graves\u2019 disease and ophthalmopathy. Front Pharmacol. 2021;12:754386. https:\/\/doi.org\/10.3389\/fphar.2021.754386.","journal-title":"Front Pharmacol"},{"issue":"3","key":"10014_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3341\/kjo.2024.0031","volume":"38","author":"JW Park","year":"2024","unstructured":"Park JW, Yoon JS. A review of novel medical treatments for thyroid eye disease. Korean J Ophthalmol. 2024;38(3):249\u201359. https:\/\/doi.org\/10.3341\/kjo.2024.0031.","journal-title":"Korean J Ophthalmol"},{"key":"10014_CR26","volume-title":"Prescribing information. Dublin","author":"Tepezza","year":"2025","unstructured":"Tepezza. Prescribing information. Dublin. Ireland: Horizon Therapeutics Ireland DAC; 2025."},{"issue":"18","key":"10014_CR27","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1614949.","journal-title":"N Engl J Med"},{"issue":"4","key":"10014_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1910434.","journal-title":"N Engl J Med"},{"issue":"4","key":"10014_CR29","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129(4):438\u201349. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017.","journal-title":"Ophthalmology"},{"issue":"9","key":"10014_CR30","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s40618-025-02595-4","volume":"48","author":"S Lin","year":"2025","unstructured":"Lin S, Ou X, Cai L, Huang W, Wen J. Efficacy and safety of tocilizumab for thyroid eye disease: a systemic review and meta-analysis. J Endocrinol Invest. 2025;48(9):1951\u201365. https:\/\/doi.org\/10.1007\/s40618-025-02595-4.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"10014_CR31","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1210\/endrev\/bnae018","volume":"45","author":"S Ugradar","year":"2024","unstructured":"Ugradar S, Malkhasyan E, Douglas RS. Teprotumumab for the treatment of thyroid eye disease. Endocr Rev. 2024;45(6):843\u201357. https:\/\/doi.org\/10.1210\/endrev\/bnae018.","journal-title":"Endocr Rev"},{"issue":"8","key":"10014_CR32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","volume":"36","author":"S Ugradar","year":"2022","unstructured":"Ugradar S, Kang J, Kossler AL, Zimmerman E, Braun J, Harrison AR, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye Lond. 2022;36(8):1553\u20139. https:\/\/doi.org\/10.1038\/s41433-021-01593-z.","journal-title":"Eye Lond"},{"issue":"6","key":"10014_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","volume":"37","author":"SB Diniz","year":"2021","unstructured":"Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37(6):583\u201391. https:\/\/doi.org\/10.1097\/IOP.0000000000001959.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"10014_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/01676830.2021.1933081","volume":"41","author":"DJ Ozzello","year":"2022","unstructured":"Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit. 2022;41(5):539\u201346. https:\/\/doi.org\/10.1080\/01676830.2021.1933081.","journal-title":"Orbit"},{"issue":"8","key":"10014_CR35","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ophtha.2021.03.006","volume":"128","author":"RC Allen","year":"2021","unstructured":"Allen RC, Bradley EA, Fante RG, Lucarelli MJ. A perspective on the current role of teprotumumab in treatment of thyroid eye disease. Ophthalmology. 2021;128(8):1125\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2021.03.006.","journal-title":"Ophthalmology"},{"issue":"2","key":"10014_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/IOP.0000000000002531","volume":"40","author":"TR Rosenblatt","year":"2024","unstructured":"Rosenblatt TR, Chiou CA, Yoon MK, Wolkow N, Lee NG, Freitag SK. Proptosis regression after teprotumumab treatment for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2024;40(2):187\u201391. https:\/\/doi.org\/10.1097\/IOP.0000000000002531.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10014_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","volume":"263","author":"CJ Hwang","year":"2024","unstructured":"Hwang CJ, Rebollo NP, Mechels KB, Perry JD. Reactivation after teprotumumab treatment for active thyroid eye disease. Am J Ophthalmol. 2024;263:152\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10014_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242153","volume":"14","author":"TD Hoang","year":"2021","unstructured":"Hoang TD, Nguyen NT, Chou E, Shakir MK. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease. BMJ Case Rep. 2021;14(5):e242153. https:\/\/doi.org\/10.1136\/bcr-2021-242153.","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10014_CR39","first-page":"134","volume":"122","author":"MD Yee","year":"2023","unstructured":"Yee MD, McCarthy J, Quinn B, Surani A. Teprotumumab-induced encephalopathy: a rare side effect of a novel therapeutic. WMJ. 2023;122(2):134\u20137.","journal-title":"WMJ"},{"issue":"2","key":"10014_CR40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.17925\/EE.2024.20.2.13","volume":"20","author":"NA Householder","year":"2024","unstructured":"Householder NA, Ray C. Teprotumumab\u2019s impact on proptosis in long-duration thyroid eye disease: a systematic review and meta-analysis. TouchREV Endocrinol. 2024;20(2):100\u20139. https:\/\/doi.org\/10.17925\/EE.2024.20.2.13.","journal-title":"TouchREV Endocrinol"},{"issue":"6","key":"10014_CR41","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41433-024-03531-1","volume":"39","author":"JC Markle","year":"2025","unstructured":"Markle JC, Johanis A, Shaia JK, Benito D, Talcott KE, Singh RP. Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis. Eye (Lond). 2025;39(6):1107\u201314. https:\/\/doi.org\/10.1038\/s41433-024-03531-1.","journal-title":"Eye (Lond)"},{"issue":"suppl 1","key":"10014_CR42","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1210\/clinem\/dgac168","volume":"107","author":"AL Kossler","year":"2022","unstructured":"Kossler AL, Douglas R, Dosiou C. Teprotumumab and the evolving therapeutic landscape in thyroid eye disease. J Clin Endocrinol Metab. 2022;107(suppl 1):S36-46. https:\/\/doi.org\/10.1210\/clinem\/dgac168.","journal-title":"J Clin Endocrinol Metab"},{"key":"10014_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/stresses4010004","volume":"4","author":"T Aoun","year":"2024","unstructured":"Aoun T, Danielova Gueorguieva D, Wu K. Orbital inflammation in thyroid eye disease: stress responses and their implications. Stresses. 2024;4:54\u201378. https:\/\/doi.org\/10.3390\/stresses4010004.","journal-title":"Stresses"},{"issue":"2","key":"10014_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002359","volume":"8","author":"K Kastrati","year":"2022","unstructured":"Kastrati K, Aletaha D, Burmester GR, Chwala E, Dejaco C, Dougados M, et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open. 2022;8(2):e002359. https:\/\/doi.org\/10.1136\/rmdopen-2022-002359.","journal-title":"RMD Open"},{"issue":"4","key":"10014_CR45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/IOP.0000000000002573","volume":"40","author":"AF Duarte","year":"2024","unstructured":"Duarte AF, Xavier NF, Sales Sanz M, Cruz AAV. Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review. Ophthalmic Plast Reconstr Surg. 2024;40(4):367\u201373. https:\/\/doi.org\/10.1097\/IOP.0000000000002573.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"8","key":"10014_CR46","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41433-024-02967-9","volume":"38","author":"M Moledina","year":"2024","unstructured":"Moledina M, Damato EM, Lee V. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye (Lond). 2024;38(8):1425\u201337. https:\/\/doi.org\/10.1038\/s41433-024-02967-9.","journal-title":"Eye (Lond)"},{"key":"10014_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u201390. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038.","journal-title":"Am J Ophthalmol"},{"key":"10014_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4939-7568-6_11","volume":"1725","author":"C Garbers","year":"2018","unstructured":"Garbers C, Rose-John S. Dissecting interleukin-6 classic- and trans-signaling in inflammation and cancer. Methods Mol Biol. 2018;1725:127\u201340. https:\/\/doi.org\/10.1007\/978-1-4939-7568-6_11.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10014_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127\u201348. https:\/\/doi.org\/10.1093\/intimm\/dxaa078.","journal-title":"Int Immunol"},{"issue":"2","key":"10014_CR50","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.4049\/jimmunol.175.2.1310","volume":"175","author":"B Chen","year":"2005","unstructured":"Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol. 2005;175(2):1310\u20139. https:\/\/doi.org\/10.4049\/jimmunol.175.2.1310.","journal-title":"J Immunol"},{"key":"10014_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2528046","volume":"2022","author":"P Zhang","year":"2022","unstructured":"Zhang P, Zhu H. Cytokines in thyroid-associated ophthalmopathy. J Immunol Res. 2022;2022:2528046. https:\/\/doi.org\/10.1155\/2022\/2528046.","journal-title":"J Immunol Res"},{"issue":"10","key":"10014_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. https:\/\/doi.org\/10.1101\/cshperspect.a016295.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"suppl 2","key":"10014_CR53","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5301\/jsrd.5000265","volume":"2","author":"E Choy","year":"2017","unstructured":"Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. J Scleroderma Relat Disord. 2017;2(suppl 2):S1\u20135.","journal-title":"J Scleroderma Relat Disord"},{"issue":"7","key":"10014_CR54","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.drudis.2021.03.018","volume":"26","author":"J Sellner","year":"2021","unstructured":"Sellner J, Sitte HH, Rommer PS. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: implications from immunology, the FcRn pathway and clinical experience. Drug Discov Today. 2021;26(7):1591\u2013601. https:\/\/doi.org\/10.1016\/j.drudis.2021.03.018.","journal-title":"Drug Discov Today"},{"issue":"4","key":"10014_CR55","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","volume":"50","author":"M Murakami","year":"2019","unstructured":"Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity. 2019;50(4):812\u201331. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.027.","journal-title":"Immunity"},{"issue":"2","key":"10014_CR56","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/eji.1830230226","volume":"23","author":"J M\u00fclberg","year":"1993","unstructured":"M\u00fclberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993;23(2):473\u201380. https:\/\/doi.org\/10.1002\/eji.1830230226.","journal-title":"Eur J Immunol"},{"issue":"1","key":"10014_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40259-023-00634-1","volume":"38","author":"AB Avci","year":"2024","unstructured":"Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned? BioDrugs. 2024;38(1):61\u201371. https:\/\/doi.org\/10.1007\/s40259-023-00634-1.","journal-title":"BioDrugs"},{"key":"10014_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155654","volume":"146","author":"T Korn","year":"2021","unstructured":"Korn T, Hiltensperger M. Role of IL-6 in the commitment of T cell subsets. Cytokine. 2021;146:155654. https:\/\/doi.org\/10.1016\/j.cyto.2021.155654.","journal-title":"Cytokine"},{"key":"10014_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2025.1544436","volume":"5","author":"J Murdock","year":"2025","unstructured":"Murdock J, Nguyen J, Hurtgen BJ, Andorfer C, Walsh J, Lin A, et al. The role of IL-6 in thyroid eye disease: an update on emerging treatments. Front Ophthalmol. 2025;5:1544436. https:\/\/doi.org\/10.3389\/fopht.2025.1544436.","journal-title":"Front Ophthalmol"},{"issue":"3","key":"10014_CR60","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1586\/17469899.2014.917960","volume":"9","author":"F Rajaii","year":"2014","unstructured":"Rajaii F, McCoy A, Smith T. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside. Expert Rev Ophthalmol. 2014;9(3):227\u201334. https:\/\/doi.org\/10.1586\/17469899.2014.917960.","journal-title":"Expert Rev Ophthalmol"},{"key":"10014_CR61","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027760","volume":"13","author":"CJ Men","year":"2021","unstructured":"Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Therapeutic Advances in Ophthalmology. 2021;13:25158414211027760. https:\/\/doi.org\/10.1177\/25158414211027760.","journal-title":"Therapeutic Advances in Ophthalmology"},{"issue":"2","key":"10014_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125\u201339. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.004.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10014_CR63","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1167\/iovs.16-21035","volume":"58","author":"NYQ Tan","year":"2017","unstructured":"Tan NYQ, Leong YY, Lang SS, Htoon ZM, Young SM, Sundar G. Radiologic parameters of orbital bone remodeling in thyroid eye disease. Invest Ophthalmol Vis Sci. 2017;58(5):2527\u201333. https:\/\/doi.org\/10.1167\/iovs.16-21035.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10014_CR64","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/EJE-22-0247","volume":"187","author":"HO Ueland","year":"2022","unstructured":"Ueland HO, Ueland G\u00c5, L\u00f8v\u00e5s K, Breivk LE, Thrane AS, Meling Stokland AE, et al. Novel inflammatory biomarkers in thyroid eye disease. Eur J Endocrinol. 2022;187(2):293\u2013300. https:\/\/doi.org\/10.1530\/EJE-22-0247.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10014_CR65","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/02713683.2021.1912783","volume":"46","author":"MA Stoynova","year":"2021","unstructured":"Stoynova MA, Shinkov AD, Georgiev GK, Kovatcheva RD. Association between clinical activity score and serum interleukin-6, interleukin-8 and interleukin-10 during systemic glucocorticoid treatment for active moderate-to-severe Graves\u2019 orbitopathy. Curr Eye Res. 2021;46(10):1503\u20138. https:\/\/doi.org\/10.1080\/02713683.2021.1912783.","journal-title":"Curr Eye Res"},{"issue":"6S","key":"10014_CR66","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/IOP.0000000000002466","volume":"39","author":"HO Ueland","year":"2023","unstructured":"Ueland HO, Neset MT, Methlie P, Ueland G\u00c5, Pakdel F, R\u00f8dahl E. Molecular biomarkers in thyroid eye disease: a literature review. Ophthalmic Plast Reconstr Surg. 2023;39(6S):S19\u201328. https:\/\/doi.org\/10.1097\/IOP.0000000000002466.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10014_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","volume":"40","author":"CA Fielding","year":"2014","unstructured":"Fielding CA, Jones GW, McLoughlin RM, McLeod L, Hammond VJ, Uceda J, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity. 2014;40(1):40\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.022.","journal-title":"Immunity"},{"key":"10014_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062045","volume":"14","author":"X Cui","year":"2023","unstructured":"Cui X, Wang F, Liu C. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves\u2019 orbitopathy. Front Immunol. 2023;14:1062045. https:\/\/doi.org\/10.3389\/fimmu.2023.1062045.","journal-title":"Front Immunol"},{"issue":"3","key":"10014_CR69","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13311-021-01175-7","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Spatola M, Schroeter CB, Wiendl H, L\u00fcnemann JD. Neonatal Fc receptor\u2013targeted therapies in neurology. Neurotherapeutics. 2022;19(3):729\u201340. https:\/\/doi.org\/10.1007\/s13311-021-01175-7.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10014_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010037","volume":"14","author":"J Traub","year":"2021","unstructured":"Traub J, Husseini L, Weber MS. B cells and antibodies as targets of therapeutic intervention in neuromyelitis optica spectrum disorders. Pharmaceuticals (Basel). 2021;14(1):37. https:\/\/doi.org\/10.3390\/ph14010037.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10014_CR71","doi-asserted-by":"publisher","first-page":"C707","DOI":"10.1152\/ajpcell.1998.274.3.C707","volume":"274","author":"GD Sempowski","year":"1998","unstructured":"Sempowski GD, Rozenblit J, Smith TJ, Phipps RP. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol. 1998;274(3):C707\u201314. https:\/\/doi.org\/10.1152\/ajpcell.1998.274.3.C707.","journal-title":"Am J Physiol"},{"issue":"2","key":"10014_CR72","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1210\/jcem.86.2.7338","volume":"86","author":"WM Wiersinga","year":"2001","unstructured":"Wiersinga WM, Prummel MF. Pathogenesis of Graves\u2019 ophthalmopathy\u2014current understanding. J Clin Endocrinol Metab. 2001;86(2):501\u20133. https:\/\/doi.org\/10.1210\/jcem.86.2.7338.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10014_CR73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/105072502753600133","volume":"12","author":"TJ Smith","year":"2002","unstructured":"Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 2002;12(3):197\u2013203. https:\/\/doi.org\/10.1089\/105072502753600133.","journal-title":"Thyroid"},{"key":"10014_CR74","doi-asserted-by":"publisher","unstructured":"Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002;32(2):477\u201385.\u00a0https:\/\/doi.org\/10.1002\/1521-4141(200202)32:2%3C;477::AID-IMMU477%3E;3.0.CO;2-U.","DOI":"10.1002\/1521-4141(200202)32:2%3C;477::AID-IMMU477%3E;3.0.CO;2-U"},{"issue":"12","key":"10014_CR75","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170(12):6348\u201354. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6348.","journal-title":"J Immunol"},{"issue":"6","key":"10014_CR76","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"BS Prabhakar","year":"2003","unstructured":"Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves\u2019 disease and ophthalmopathy. Endocr Rev. 2003;24(6):802\u201335. https:\/\/doi.org\/10.1210\/er.2002-0020.","journal-title":"Endocr Rev"},{"issue":"8","key":"10014_CR77","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362(8):726\u201338. https:\/\/doi.org\/10.1056\/NEJMra0905750.","journal-title":"N Engl J Med"},{"issue":"7","key":"10014_CR78","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.18240\/ijo.2019.07.24","volume":"12","author":"ZM Wang","year":"2019","unstructured":"Wang ZM, Wang ZY, Lu Y. The role of cell mediated immunopathogenesis in thyroid-associated ophthalmopathy. Int J Ophthalmol. 2019;12(7):1209\u201314. https:\/\/doi.org\/10.18240\/ijo.2019.07.24.","journal-title":"Int J Ophthalmol"},{"issue":"12","key":"10014_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/life12122084","volume":"12","author":"R Rashad","year":"2022","unstructured":"Rashad R, Pinto R, Li E, Sohrab M, Distefano AG. Thyroid eye disease. Life. 2022;12(12):2084. https:\/\/doi.org\/10.3390\/life12122084.","journal-title":"Life"},{"issue":"8","key":"10014_CR80","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1210\/jcem.81.8.8768861","volume":"81","author":"M Salvi","year":"1996","unstructured":"Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease. J Clin Endocrinol Metab. 1996;81(8):2976\u20139. https:\/\/doi.org\/10.1210\/jcem.81.8.8768861.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10014_CR81","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/eje.0.1430197","volume":"143","author":"M Salvi","year":"2000","unstructured":"Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, et al. Serum concentrations of proinflammatory cytokines in graves\u2019 disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol. 2000;143(2):197\u2013202. https:\/\/doi.org\/10.1530\/eje.0.1430197.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10014_CR82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/08916939708996275","volume":"25","author":"I Moln\u00e1r","year":"1997","unstructured":"Moln\u00e1r I, Balazs C. High circulating IL-6 level in Graves\u2019 ophthalmopathy. Autoimmunity. 1997;25(2):91\u20136. https:\/\/doi.org\/10.3109\/08916939708996275.","journal-title":"Autoimmunity"},{"issue":"3","key":"10014_CR83","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-2249.2000.01335.x","volume":"121","author":"IMMJ Wakelkamp","year":"2000","unstructured":"Wakelkamp IMMJ, Gerding MN, Van Der Meer JWC, Prummel MF, Wiersinga WM. Both Th1- and Th2-derived cytokines in serum are elevated in Graves\u2019 ophthalmopathy. Clin Exp Immunol. 2000;121(3):453\u20137. https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01335.x.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10014_CR84","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/07435800.2011.635622","volume":"37","author":"M Slowik","year":"2012","unstructured":"Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, Kapelko-Slowik K, Dybko J, Wolowiec D, et al. CD8\u2009+\u2009CD28- lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves\u2019 orbitopathy and correlate with disease activity. Endocr Res. 2012;37(2):89\u201395. https:\/\/doi.org\/10.3109\/07435800.2011.635622.","journal-title":"Endocr Res"},{"issue":"1","key":"10014_CR85","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/thy.2009.0278","volume":"20","author":"S Kumar","year":"2010","unstructured":"Kumar S, Schiefer R, Coenen MJ, Bahn RS. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves\u2019 orbital preadipocyte fibroblasts. Thyroid. 2010;20(1):59\u201365. https:\/\/doi.org\/10.1089\/thy.2009.0278.","journal-title":"Thyroid"},{"issue":"1","key":"10014_CR86","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1038\/s41598-018-29113-2","volume":"8","author":"E Kishazi","year":"2018","unstructured":"Kishazi E, Dor M, Eperon S, Oberic A, Turck N, Hamedani M. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy. Sci Rep. 2018;8(1):10792. https:\/\/doi.org\/10.1038\/s41598-018-29113-2.","journal-title":"Sci Rep"},{"issue":"4","key":"10014_CR87","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/thy.2011.0248","volume":"22","author":"B Ujhelyi","year":"2012","unstructured":"Ujhelyi B, Gogolak P, Erdei A, Nagy V, Balazs E, Rajnavolgyi E, et al. Graves\u2019 orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines. Thyroid. 2012;22(4):407\u201314. https:\/\/doi.org\/10.1089\/thy.2011.0248.","journal-title":"Thyroid"},{"issue":"1","key":"10014_CR88","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1871530319666190618142215","volume":"20","author":"RH Song","year":"2020","unstructured":"Song RH, Wang B, Yao QM, Li Q, Jia X, Zhang JA. Proteomics screening of differentially expressed cytokines in tears of patients with Graves\u2019 ophthalmopathy. Endocr Metab Immune Disord Drug Targets. 2020;20(1):87\u201395. https:\/\/doi.org\/10.2174\/1871530319666190618142215.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"12","key":"10014_CR89","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1089\/thy.2022.0173","volume":"32","author":"YP Hai","year":"2022","unstructured":"Hai YP, Saeed MEM, Ponto KA, Elflein HM, Lee ACH, Fang S, et al. A multicenter, single-blind, case-control, immunohistochemical study of orbital tissue in thyroid eye disease. Thyroid. 2022;32(12):1547\u201358. https:\/\/doi.org\/10.1089\/thy.2022.0173.","journal-title":"Thyroid"},{"issue":"3","key":"10014_CR90","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1089\/thy.2022.0254","volume":"33","author":"Y Lu","year":"2023","unstructured":"Lu Y, Wang Y, Wang Y, Wu Y, Huang Y, Liu X, et al. M1-like macrophages modulate fibrosis and inflammation of orbital fibroblasts in Graves\u2019 orbitopathy: potential relevance to soluble interleukin-6 receptor. Thyroid. 2023;33(3):338\u201350. https:\/\/doi.org\/10.1089\/thy.2022.0254.","journal-title":"Thyroid"},{"issue":"10","key":"10014_CR91","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1089\/105072501753210984","volume":"11","author":"SC Jyonouchi","year":"2001","unstructured":"Jyonouchi SC, Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves\u2019 ophthalmopathy. Thyroid. 2001;11(10):929\u201334. https:\/\/doi.org\/10.1089\/105072501753210984.","journal-title":"Thyroid"},{"issue":"9","key":"10014_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075100","volume":"8","author":"N Raychaudhuri","year":"2013","unstructured":"Raychaudhuri N, Fernando R, Smith TJ. Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions. PLoS One. 2013;8(9):e75100. https:\/\/doi.org\/10.1371\/journal.pone.0075100.","journal-title":"PLoS One"},{"issue":"3","key":"10014_CR93","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1210\/jcem.85.3.6433","volume":"85","author":"Y Hiromatsu","year":"2000","unstructured":"Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2000;85(3):1194\u20139. https:\/\/doi.org\/10.1210\/jcem.85.3.6433.","journal-title":"J Clin Endocrinol Metab"},{"key":"10014_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839380","volume":"13","author":"L Cabezas","year":"2022","unstructured":"Cabezas L, Jouve T, Malvezzi P, Janbon B, Giovannini D, Rostaing L, et al. Tocilizumab and active antibody-mediated rejection in kidney transplantation: a literature review. Front Immunol. 2022;13:839380. https:\/\/doi.org\/10.3389\/fimmu.2022.839380.","journal-title":"Front Immunol"},{"key":"10014_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648732","volume":"12","author":"S Fang","year":"2021","unstructured":"Fang S, Lu Y, Huang Y, Zhou H, Fan X. Mechanisms that underly T cell immunity in Graves\u2019 orbitopathy. Front Endocrinol (Lausanne). 2021;12:648732. https:\/\/doi.org\/10.3389\/fendo.2021.648732.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10014_CR96","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40123-019-00226-9","volume":"9","author":"NM Hodgson","year":"2020","unstructured":"Hodgson NM, Rajaii F. Current understanding of the progression and management of thyroid associated orbitopathy: a systematic review. Ophthalmol Ther. 2020;9(1):21\u201333. https:\/\/doi.org\/10.1007\/s40123-019-00226-9.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10014_CR97","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcjo.2020.07.020","volume":"56","author":"RZ Silkiss","year":"2021","unstructured":"Silkiss RZ, Paap MK, Roelofs KA, Agi J, Weis E. Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab. Can J Ophthalmol. 2021;56(1):66\u201370. https:\/\/doi.org\/10.1016\/j.jcjo.2020.07.020.","journal-title":"Can J Ophthalmol"},{"key":"10014_CR98","unstructured":"Genentech\u2019s Actemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition. News release. Genentech, Inc. March 4, 2021. Accessed September 12, 2024. https:\/\/www.gene.com\/media\/press-releases\/14897\/2021-03-04\/genentechs-actemra-becomes-the-first-bio"},{"key":"10014_CR99","volume-title":"Prescribing information. South San Francisco","author":"Actemra","year":"2025","unstructured":"Actemra. Prescribing information. South San Francisco. CA: Genentech, Inc.; 2025."},{"issue":"10","key":"10014_CR100","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40265-014-0249-x","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A, Patel T. Siltuximab: first global approval. Drugs. 2014;74(10):1147\u201352. https:\/\/doi.org\/10.1007\/s40265-014-0249-x.","journal-title":"Drugs"},{"key":"10014_CR101","volume-title":"Prescribing information. Bridgewater","author":"Kevzara","year":"2018","unstructured":"Kevzara. Prescribing information. Bridgewater. NJ: sanofi-aventis U.S. LLC; 2018."},{"key":"10014_CR102","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.copsyc.2015.03.004","volume":"5","author":"BW Heckman","year":"2015","unstructured":"Heckman BW, Mathew AR, Carpenter MJ. Treatment burden and treatment fatigue as barriers to health. Curr Opin Psychol. 2015;5:31\u20136. https:\/\/doi.org\/10.1016\/j.copsyc.2015.03.004.","journal-title":"Curr Opin Psychol"},{"key":"10014_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1186105","volume":"14","author":"G Boutzios","year":"2023","unstructured":"Boutzios G, Chatzi S, Goules AV, Mina A, Charonis GC, Vlachoyiannopoulos PG, et al. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study. Front Endocrinol (Lausanne). 2023;14:1186105. https:\/\/doi.org\/10.3389\/fendo.2023.1186105.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10014_CR104","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10792-024-03117-6","volume":"44","author":"C Lee","year":"2024","unstructured":"Lee C, Park JW, Kim YD, Woo KI. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study. Int Ophthalmol. 2024;44(1):179. https:\/\/doi.org\/10.1007\/s10792-024-03117-6.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10014_CR105","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/09273948.2018.1545914","volume":"28","author":"T Maldiney","year":"2020","unstructured":"Maldiney T, Deschasse C, Bielefeld P. Tocilizumab for the management of corticosteroid-resistant mild to severe Graves\u2019 ophthalmopathy, a report of three cases. Ocul Immunol Inflamm. 2020;28(2):281\u20134. https:\/\/doi.org\/10.1080\/09273948.2018.1545914.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10014_CR106","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14655","volume":"97","author":"L Moi","year":"2022","unstructured":"Moi L, Hamedani M, Ribi C. Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab. Clin Endocrinol (Oxf). 2022;97(3):363\u201370. https:\/\/doi.org\/10.1111\/cen.14655.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10014_CR107","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.medcli.2022.05.007","volume":"160","author":"R Pamp\u00edn-S\u00e1nchez","year":"2023","unstructured":"Pamp\u00edn-S\u00e1nchez R, Mart\u00ednez-Mugica-Barbosa C, Fonseca-Aizpuru EM, Barbaz\u00e1n-V\u00e1zquez FJ, Fern\u00e1ndez-Gonz\u00e1lez B, Buznego-S\u00fa\u00e1rez L. Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease. Med Clin (Barc). 2023;160(3):113\u20137. https:\/\/doi.org\/10.1016\/j.medcli.2022.05.007.","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"10014_CR108","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV Perez-Moreiras","year":"2014","unstructured":"Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC. Treatment of active corticosteroid-resistant Graves\u2019 orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30(2):162\u20137. https:\/\/doi.org\/10.1097\/IOP.0000000000000037.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"10014_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040706","volume":"10","author":"JV P\u00e9rez-Moreiras","year":"2021","unstructured":"P\u00e9rez-Moreiras JV, Varela-Agra M, Prada-S\u00e1nchez MC, Prada-Ramallal G. Steroid-resistant Graves\u2019 orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience. J Clin Med. 2021;10(4):706. https:\/\/doi.org\/10.3390\/jcm10040706.","journal-title":"J Clin Med"},{"issue":"9","key":"10014_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092816","volume":"9","author":"L S\u00e1nchez-Bilbao","year":"2020","unstructured":"S\u00e1nchez-Bilbao L, Mart\u00ednez-L\u00f3pez D, Revenga M, L\u00f3pez-V\u00e1zquez A, Valls-Pascual E, Atienza-Mateo B, et al. Anti-IL-6 receptor tocilizumab in refractory Graves\u2019 orbitopathy: national multicenter observational study of 48 patients. J Clin Med. 2020;9(9):2816. https:\/\/doi.org\/10.3390\/jcm9092816.","journal-title":"J Clin Med"},{"issue":"10","key":"10014_CR111","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00417-019-04419-7","volume":"257","author":"A Leszczynska","year":"2019","unstructured":"Leszczynska A, Molins B, Fernandez E, Adan A, Ortiz-Perez S. Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2307\u201314. https:\/\/doi.org\/10.1007\/s00417-019-04419-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10014_CR112","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/09273948.2020.1808688","volume":"30","author":"A Bennedjai","year":"2022","unstructured":"Bennedjai A, Bouheraoua N, Gatfosse M, Dupasquier-Fediaevsky L, Errera MH, Tazartes M, et al. Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant graves\u2019 orbitopathy. Ocul Immunol Inflamm. 2022;30(2):500\u20135. https:\/\/doi.org\/10.1080\/09273948.2020.1808688.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10014_CR113","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1210\/clinem\/dgac606","volume":"108","author":"A Mohamed","year":"2023","unstructured":"Mohamed A, Tzoulis P, Kossler AL, Dosiou C. New onset or deterioration of thyroid eye disease after mRNA SARS-CoV-2 vaccines: report of 2 cases and literature review. J Clin Endocrinol Metab. 2023;108(4):979\u201385. https:\/\/doi.org\/10.1210\/clinem\/dgac606.","journal-title":"J Clin Endocrinol Metab"},{"key":"10014_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1160936","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Chen J, Lin K, Yu X. Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves\u2019ophthalmopathy: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1160936. https:\/\/doi.org\/10.3389\/fendo.2023.1160936.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10014_CR115","doi-asserted-by":"publisher","first-page":"e886","DOI":"10.1210\/clinem\/dgae711","volume":"110","author":"A Sun","year":"2025","unstructured":"Sun A, Wang X, Qu J, Wu Y. The efficacy and safety of intravenous Tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and single-arm meta-analysis. J Clin Endocrinol Metab. 2025;110(3):e886\u201396. https:\/\/doi.org\/10.1210\/clinem\/dgae711.","journal-title":"J Clin Endocrinol Metab"},{"key":"10014_CR116","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ajoc.2017.07.001","volume":"7","author":"DJ Russell","year":"2017","unstructured":"Russell DJ, Wagner LH, Seiff SR. Tocilizumab as a steroid sparing agent for the treatment of Graves\u2019 orbitopathy. Am J Ophthalmol Case Rep. 2017;7:146\u20138. https:\/\/doi.org\/10.1016\/j.ajoc.2017.07.001.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"10014_CR117","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/tjo.tjo_59_21","volume":"12","author":"SM Stevens","year":"2022","unstructured":"Stevens SM, Pirakitikulr N, Lee BW. Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers. Taiwan J Ophthalmol. 2022;12(1):39\u201343. https:\/\/doi.org\/10.4103\/tjo.tjo_59_21.","journal-title":"Taiwan J Ophthalmol"},{"issue":"6","key":"10014_CR118","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2174\/1871530318666180702150243","volume":"18","author":"CA Canas","year":"2018","unstructured":"Canas CA, Bonilla-Abadia F, Vallejo K, Rengifo HM, Gallon MA, Tobon GJ. Successful treatment for severe thyroid-associated ophthalmopathy with tocilizumab. Endocr Metab Immune Disord Drug Targets. 2018;18(6):665\u20137. https:\/\/doi.org\/10.2174\/1871530318666180702150243.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"3","key":"10014_CR119","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40618-022-01955-8","volume":"46","author":"J du Abeillon- Payrat","year":"2023","unstructured":"du Abeillon- Payrat J, Grunenwald S, Gall E, Ladsous M, Raingeard I, Caron P. Graves\u2019 orbitopathy post-SARS-CoV-2 vaccines: report on six patients. J Endocrinol Invest. 2023;46(3):617\u201327. https:\/\/doi.org\/10.1007\/s40618-022-01955-8.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10014_CR120","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1097\/IOP.0000000000001346","volume":"35","author":"T Copperman","year":"2019","unstructured":"Copperman T, Idowu OO, Kersten RC, Vagefi MR. Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast Reconstr Surg. 2019;35(3):e64\u20136. https:\/\/doi.org\/10.1097\/IOP.0000000000001346.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"10014_CR121","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55100","volume":"16","author":"BR Meher","year":"2024","unstructured":"Meher BR, Mohanty RR, Dash A. Review of satralizumab for neuromyelitis optica spectrum disorder: a new biologic agent targeting the interleukin-6 receptor. Cureus. 2024;16(2):e55100. https:\/\/doi.org\/10.7759\/cureus.55100.","journal-title":"Cureus"},{"issue":"5","key":"10014_CR122","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(20)30078-8.","journal-title":"Lancet Neurol"},{"issue":"22","key":"10014_CR123","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1901747.","journal-title":"N Engl J Med"},{"issue":"1","key":"10014_CR124","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200071","volume":"10","author":"I Kleiter","year":"2023","unstructured":"Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200071. https:\/\/doi.org\/10.1212\/NXI.0000000000200071.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3 suppl","key":"10014_CR125","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1177\/13524585231198396","volume":"29","author":"J Palace","year":"2023","unstructured":"Palace J, Traboulsee A, Saiz A, De Seze J, Kleiter I, Bennett JL, et al. Long-term efficacy of satralizumab in patients with AQP4-IgG\u2009+\u2009NMOSD: updated analysis from the open-label SAkuraMoon study. Mult Scler. 2023;29(3 suppl):1051\u201381. https:\/\/doi.org\/10.1177\/13524585231198396.","journal-title":"Mult Scler"},{"issue":"5","key":"10014_CR126","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s40120-024-00640-7","volume":"13","author":"T Yamamura","year":"2024","unstructured":"Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, et al. Safety and effectiveness of satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 6-month interim analysis of post-marketing surveillance. Neurol Ther. 2024;13(5):1361\u201383. https:\/\/doi.org\/10.1007\/s40120-024-00640-7.","journal-title":"Neurol Ther"},{"key":"10014_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106384","volume":"98","author":"K Fujihara","year":"2025","unstructured":"Fujihara K, Isobe N, Miyamoto K, Niino M, Nakahara J, Hattori S, et al. Effectiveness of satralizumab in a real-world clinical setting in Japan: interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: a six-month interim analysis of a multicenter medical chart review. Mult Scler Relat Disord. 2025;98:106384. https:\/\/doi.org\/10.1016\/j.msard.2025.106384.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10014_CR128","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1923366","volume":"13","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Hashii N, Tada M, Ishii-Watabe A. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: analysis of FcRn-binding engineered antibodies and an Fc fusion protein. mAbs. 2021;13(1):1923366. https:\/\/doi.org\/10.1080\/19420862.2021.1923366.","journal-title":"mAbs"},{"issue":"11","key":"10014_CR129","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nbt.1691","volume":"28","author":"T Igawa","year":"2010","unstructured":"Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28(11):1203\u20137. https:\/\/doi.org\/10.1038\/nbt.1691.","journal-title":"Nat Biotechnol"},{"issue":"14","key":"10014_CR130","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo YA. Satralizumab: first approval. Drugs. 2020;80(14):1477\u201382. https:\/\/doi.org\/10.1007\/s40265-020-01380-2.","journal-title":"Drugs"},{"issue":"7","key":"10014_CR131","first-page":"3043","volume":"65","author":"K Erickson","year":"2024","unstructured":"Erickson K, Comisar C, Seiff S, Chyung Y, Iarrobino R, DeGoma E, et al. Dose selection modeling for a phase 2b trial investigating TOUR006, an anti-il-6 antibody, for treatment of thyroid eye disease. Invest Ophthalmol Vis Sci. 2024;65(7):3043.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10014_CR132","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/annrheumdis-2022-eular.4039","volume":"81","author":"V Moreira Navarrete","year":"2022","unstructured":"Moreira Navarrete V, Toyos S\u00e1enz de Miera F, Garrido Hermosilla A, Mu\u00f1oz Reinoso P, Madrigal Dom\u00ednguez M, P\u00e9rez Venegas J. AB1315. Sarilumab in patients with refractory graves\u2019 orbitopathy. Effectiveness and safety in a series of cases in clinical practice. Ann Rheum Dis. 2022;81:1764\u20135.","journal-title":"Ann Rheum Dis"},{"key":"10014_CR133","doi-asserted-by":"publisher","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016(10). https:\/\/doi.org\/10.1089\/thy.2016.0229.","DOI":"10.1089\/thy.2016.0229"},{"key":"10014_CR134","unstructured":"R-Pharm. Olokizumab. 2024. https:\/\/olokizumab.com. Accessed October 17, 2024."}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-10014-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-025-10014-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-10014-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:18:31Z","timestamp":1781633911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-025-10014-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":134,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10014"],"URL":"https:\/\/doi.org\/10.1007\/s11154-025-10014-5","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"D.G.E. is a consultant for Calilia. A.A. is a consultant for Amgen, Chugai, and Roche, and is a principal investigator for trials for Chugai, Immunovant, and Roche. C.A.B. is a consultant for Amgen, argenx and Roche\/Genentech, Inc. and his academic activities are partially funded by an unrestricted grant from Research to Prevent Blindness. F.R. is a consultant for Acelyrin, Amgen, and Khartis, and is a principal investigator for trials for Immunovant, Roche, and Viridian. M.S. is a consultant and advisory board member for Amgen, argenx, IBSA, Immunovant, Lycia, Merck, Roche, Third Rock Ventures, Tourmaline, and Viridian. M.S.-S. is a consultant for Amgen and Immunovant, and is a principal investigator for trials for Amgen, argenx, Immunovant, Roche, Sling, and Viridian. L.B. is an employee of and holds stocks or stock options in Roche Products Ltd. O.O.I. is an employee of and holds stocks or stock options in Genentech, Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}